As clinical games emerge as a new tool for diagnosing and treating cognitive health, it is important to understand how these tools work and the ways in which these tools are validated, as well as how to realize their full potential.
An effective risk mitigation model requires the development of a structured approach to risk identification, analysis and control, from trial inception to completion.
The Cancer Research UK recently decided to have its Center for Drug Development adopt a risk-based monitoring approach across its entire portfolio of clinical trials.
Building on more than a decade of initiatives to spur pediatric labeling on drugs and biologics, regulatory authorities are bolstering incentives for sponsors to develop more information faster on the use of medicines in children.
Medidata took a look at how eCRF design complexity correlates with the number of migrations performed while a study is actively collecting subject data.
Tufts CSDD estimates that the cost to develop a new prescription medicine that gains marketing approval is now $2.6 billion.